DARE
NASDAQDare Bioscience Inc.
Price$2.00-0.00 (-0.25%)
02:30 PM07:30 PM
News · 26 weeks42-40%
2025-12-142026-06-07
Mix2990d
- SEC Filings16(55%)
- Other9(31%)
- Earnings4(14%)
Latest news
25 items- PRDaré Bioscience Announces the Upcoming Launch of Flora Sync LF5™ Vaginal Probiotic CapsulesFirst Product Revenue Expected This Month, Opening New Commercial Chapter for Women's Health Innovator Limited-Time Launch Offer: 30% Off + Free Shipping SAN DIEGO, June 04, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced the upcoming commercial launch of Flora Sync LF5™, a vaginal probiotic capsule formulated specifically to restore microbiome balance and support lasting vaginal comfort. The launch represents a milestone for Daré, as the company expects to generate its first direct consumer product revenue in June
- SECSEC Form DEFA14A filed by Dare Bioscience Inc.DEFA14A - Dare Bioscience, Inc. (0001401914) (Filer)
- SECSEC Form DEFA14A filed by Dare Bioscience Inc.DEFA14A - Dare Bioscience, Inc. (0001401914) (Filer)
- PRDaré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical CancerReceipt of award notice for second $1.0 million tranche of NIAID funding brings total NIH funding award for DARE-HPV to $2.0 millionFunding award milestone follows Daré's announcement last week of the initiation of its Phase 2 clinical study of DARE-HPV — representing the first time women with persistent high-risk HPV infection may have access to this pharmacologic treatment as part of a clinical trialDARE-HPV targets high-risk HPV infection, the cause of virtually all cervical cancer cases in the U.S., for which there are currently no FDA-approved pharmacologic treatmentsAward reflects Daré's strategy of leveraging non-dilutive government funding, including both NIH grants and ARPA-H contra
- SECDare Bioscience Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities8-K - Dare Bioscience, Inc. (0001401914) (Filer)
- PRDaré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved TherapiesEach year, an estimated six million women in the United States acquire a high-risk HPV infection — and there are no FDA-approved treatments DARE-HPV development is backed by a $10 million U.S. government (ARPA-H)-funded contract; topline data readout expected in 2027 SAN DIEGO, May 18, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced the initiation of its Phase 2 clinical study of DARE-HPV, an investigational, proprietary fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert, designed to evalu
- SECSEC Form 10-Q filed by Dare Bioscience Inc.10-Q - Dare Bioscience, Inc. (0001401914) (Filer)
- SECDare Bioscience Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Dare Bioscience, Inc. (0001401914) (Filer)
- PRDaré Bioscience Reports First Quarter 2026 Financial Results and Provides Business UpdateCompany Highlights Second Positive DSMB Review of Interim Data from Ovaprene® Phase 3 Clinical Trial, DARE to PLAY™ Anticipated Dispensing Commencement and Flora Sync LF5™ Commercial Launch Summer 2026; First Product Revenue Expected in June 2026; Call Hosted During National Women's Health Week. Conference Call and Webcast Today at 4:30 p.m. ET "We are hosting our financial results and business update call from New York, in the middle of National Women's Health Week," said Sabrina Martucci Johnson, President and Chief Executive Officer of Daré Bioscience. "Daré was built on the conviction that women's health is an investment-grade category – not a niche, not a nice-to-have, not a pink ribb
- PRPositive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free ContraceptiveSecond Positive DSMB Review Supports Continued Study Progress Interim Phase 3 Results Support Ovaprene's Differentiation as a First-in-Category, Hormone-Free, Intravaginal Monthly Contraceptive SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced positive interim safety and efficacy results from its ongoing Phase 3 clinical trial evaluating the contraceptive effectiveness, safety and acceptability of Ovaprene®, the company's investigational monthly, hormone-free intravaginal contraceptive. There current
- SECDare Bioscience Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities8-K - Dare Bioscience, Inc. (0001401914) (Filer)
- PRDaré Bioscience to Host First Quarter 2026 Financial Results and Company Update Conference Call and Webcast on May 14, 2026SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, May 14, 2026, to review its financial results for the quarter ended March 31, 2026 and to provide a company update. To access the conference call via phone, dial (646) 307-1963 or (800) 715-9871 (toll-free). The conference ID number for the call is 2531472. The live webcast can be accessed under "Presentations, Events & Webcasts" in the Investors section of the company's website at ht
- SECSEC Form DEFA14A filed by Dare Bioscience Inc.DEFA14A - Dare Bioscience, Inc. (0001401914) (Filer)
- SECSEC Form DEF 14A filed by Dare Bioscience Inc.DEF 14A - Dare Bioscience, Inc. (0001401914) (Filer)
- SECDare Bioscience Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Dare Bioscience, Inc. (0001401914) (Filer)
- SECDare Bioscience Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities8-K - Dare Bioscience, Inc. (0001401914) (Filer)
- SECDare Bioscience Inc. filed SEC Form 8-K: Leadership Update8-K - Dare Bioscience, Inc. (0001401914) (Filer)
- SECSEC Form PRE 14A filed by Dare Bioscience Inc.PRE 14A - Dare Bioscience, Inc. (0001401914) (Filer)
- SECDare Bioscience Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities8-K - Dare Bioscience, Inc. (0001401914) (Filer)
- SECSEC Form QUALIF filed by Dare Bioscience Inc.QUALIF - Dare Bioscience, Inc. (0001401914) (Filer)
- SECSEC Form 1-A POS filed by Dare Bioscience Inc.1-A POS - Dare Bioscience, Inc. (0001401914) (Filer)
- SECSEC Form 253G2 filed by Dare Bioscience Inc.253G2 - Dare Bioscience, Inc. (0001401914) (Filer)
- SECSEC Form 10-K filed by Dare Bioscience Inc.10-K - Dare Bioscience, Inc. (0001401914) (Filer)
- SECDare Bioscience Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Dare Bioscience, Inc. (0001401914) (Filer)
- PRDaré Bioscience Reports Full Year 2025 Financial Results and Provides Business UpdateCompany Highlights Commercial Launch of DARE to PLAY™ Sildenafil Cream, Pipeline of Women's Health Solutions, and Multiple Near-Term Potential Catalysts Conference Call and Webcast Today at 4:30 p.m. ET SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today reported financial results for the year ended December 31, 2025, and provided a business update. "We are not a company that is just getting into women's health. We are a women's health biotech company – and we believe 2026 is the year investors wi
DARE FAQ
7 questionsWhat does Dare Bioscience Inc. do?
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing products for women's health in the United States. The company develops therapies in the areas of contraception, fertility, and sexual and vaginal health. Its products in advanced clinical development include DARE-BV1, a bioadhesive hydrogel formulated with clindamycin phosphate 2% to treat bacterial vaginosis in a single administration that has completed Phase 3 clinical trials; Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil...Where does DARE stock trade?
Dare Bioscience Inc. (DARE) is listed on NASDAQ.What sector and industry is DARE in?
Dare Bioscience Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Dare Bioscience Inc. go public?
Dare Bioscience Inc. (DARE) completed its IPO in 2014.What are analysts saying about DARE?
Dare Bioscience Inc. has had 1 recent analyst action on file. The most recent action was from Roth Capital: Buy with a $1100.00 price target on 2021-06-30. Recent price targets cluster around $1100.00.What companies are similar to DARE?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare DARE side-by-side with any of them on Quantisnow.How can I track DARE on Quantisnow?
Quantisnow aggregates Dare Bioscience Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DARE to receive live email and push alerts on every new disclosure.